2025 in Review: RegMed XB Highlights

− 0 min read

As 2026 begins, it is a good moment to reflect on the strong foundation built over the past year and the progress already underway at RegMed XB. 

RegMed XB’s 2025 marked another year of strong progress and growing. Regenerative medicine continued as a key approach to addressing the rising burden of chronic diseases, supported by expanding collaborations and concrete translational advances.

Bernard Mulder, General Director RegMed XB

Click to read the Highlights 2025 directly in the browser

  • Download Highlights 2025